Hyperprolactinemia-associated erectile dysfunction: retrospective cohort evaluating the effect of prolactin...

Area of Science:

• Endocrinology
• Urology
• Sexual Medicine

Background:

• Hyperprolactinemia, an endocrine disorder, is an underrecognized cause of erectile dysfunction (ED) in men.
• Elevated prolactin levels can negatively impact male sexual function, often coexisting with hypogonadism.

Purpose of the Study:

• To assess the impact of normalizing prolactin (PRL) levels on erectile function in men with ED and hyperprolactinemia.
• To evaluate the efficacy of treating hyperprolactinemia as a strategy to improve erectile function.

Main Methods:

• Retrospective analysis of 20 male patients diagnosed with hyperprolactinemia and ED.
• Patients were categorized into three groups: conservative (no hyperprolactinemia treatment), pharmacotherapy with dopaminergic agonists (Dostinex), and neurosurgical intervention (Surgery).
• All patients received phosphodiesterase type 5 inhibitors (PDE5I) for ED management.

Main Results:

• Successful treatment of hyperprolactinemia resulted in normalized PRL levels in all treated patients.
• Significant improvements in erectile function, measured by the International Index of Erectile Function-5 (IIEF-5) scores, were observed in the Dostinex and Surgery groups.
• A trend towards improvement in IIEF-5 scores was noted in the conservative group.

Conclusions:

• Normalization of PRL levels through pharmacological or surgical treatment positively impacts male sexual health and erectile function.
• Comprehensive hormonal assessment, including PRL measurement, is crucial in managing male sexual dysfunction.
• Combining PDE5I therapy with hyperprolactinemia treatment offers an effective therapeutic strategy for men with ED.